Date: 2017-03-20
Type of information: Fundraising
Company: Pulmocide (UK)
Investors: SR One (UK) Longwood Fund SV Life Sciences (USA - MA) F-Prime Capital (USA - MA) Johnson &Johnson Innovation - JJDC (USA-NJ) Touchstone Innovations (UK)
Amount: $30.4 million
Funding type: series B financing round
Planned used: Pulmocide will use the proceeds of this financing round to progress two wholly-owned assets, PC786 and PC945, through early clinical development. Pulmocide is on track to deliver proof of concept data in RSV with its inhaled RSV antiviral agent (PC786) in human RSV challenge and in infants hospitalised with bronchiolitis due to RSV infection. Pulmocide will also be progressing PC945, a potent azole antifungal for the treatment of pulmonary aspergillosis, including fungal asthma, pulmonary aspergilloma, Aspergillus infections in lung transplant recipients and patients with cystic fibrosis.
Others: * On March 20, 2017, Pulmocide, a UK-based drug discovery company developing novel compounds designed for inhaled delivery to treat respiratory syncytial virus (RSV) and pulmonary aspergillosis, announced the completion of a $30.4 million Series B financing round. The round was led by new investor SR One and included Longwood Fund plus existing investors SV Life Sciences, F-Prime Capital, Johnson & Johnson Innovation - JJDC and Touchstone Innovations.
Therapeutic area: Infectious diseases - Respiratory diseases
